Over 250 delegates representing the leading research & academic institutions and clinical research institutions in the USA, as well as leading pharmaceutical and biotech companies from around the globe.
Over 20 presentations dedicated to genome editing technologies and the applications of genome editing in a range of therapeutic areas, including muscular dystrophy, cardiovascular diseases, genetic disorders and immunotherapies.
Co-located with our 2nd Annual Next Generation Sequencing USA Congress and 2nd Annual Single Cell Analysis USA Congress, delegates will also have access to over 50 further presentations focusing on the therapeutic application of next generation sequencing technologies, transferring NGS into the clinic, single cell ‘omics, singlecell analysis technologies.
Including 2 interactive streams:
• Genome Editing Techniques
• Therapeutic Applications of Genome Editing
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities
Oxford Global are proud to present the inaugural Genome Editing USA Congress taking place on the 3rd & 4th October 2016, at The Westin Boston Waterfront Hotel, Boston, USA. Over the two days this prestigious congress will bring together over 250 senior level attendees from both academia and pharma to discuss the most crucial challenges in genome editing, genome engineering, next generation sequencing and single cell analysis.
Genome editing tools, especially the recent discovery of the CRISPR/Cas-9 system, are rapidly altering the field of genomics, and exciting advances are being made in the development of molecular modifications to treat the underlying causes of genetic diseases.
On Day 1 of the conference hear from key experts in the field to discuss the application of genome editing in therapeutic areas such as muscular dystrophy, cardiovascular disease, immunotherapy, genetic diseases and precision medicine.
On Day 2 our renowned speakers will discuss research and advances in the use of different genome editing techniques such as CRISPR, TALENs and ZFNs. Presentations will include how to achieve genome editing control at a whole genome scale as well as addressing challenges in the use of different types of gene-editing technologies.